Phospholipids pp 133-165 | Cite as

Therapeutic Aspects of Liposomes

  • F. Puisieux
  • G. Barratt
  • L. Roblot-Treupel
  • J. Delattre
  • P. Couvreur
  • J. Ph. Devissaguet

Abstract

The fate of a drug after administration in vivo is determined by a combination of several processes: distribution and elimination when given intravenously and absorption, distribution and elimination when an extravascular route is used. Regardless of the mechanisms involved, each of these processes depends mainly on the physico-chemical properties of the drug and therefore, for the most part, on its chemical structure.

Keywords

Visceral Leishmaniasis Drug Carrier Liposomal Amphotericin Systemic Fungal Infection Free Doxorubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations used

ADM

adriamycin

AMB

amphotericin B

Ara-C

cytosine arabinoside

ATP

adenosine triphosphate

Chol

cholesterol

DCP

dicetylphosphate

DMPC

dimyristoylphosphatidylcholine

DMPG

dimyristoylphosphatidylglycerol

DOPC

dioleoylphosphatidylcholine

DOPE

dioleoylphosphatidylethanolamine

DPPC

dipalmitoylphosphatidylcholine

DTPA

diethylene triamine pentaacetic acid

MDP

muramyldipeptide

MLV

multilamellar vesicles

MTP-PE

muramyltripeptide-phosphatidylethanolamine

OA

oleic acid

PC

phosphatidylcholine

PS

phosphatidylserine

rIFN

recombinant human interferon

RES

reticuloendothelial system

REV

reverse phase vesicles

SA

stearylamine

SOPE

DN-succinyldioleoylphosphatidylethanolamine

SUV

small unilamellar vesicles

Tc

phase transition temperature

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adinolfi L.E., Bonventre P.F., Van Der Pas M. and Eppstein D.A., 1985, Synergistic effect of glucanthine and a liposomeencapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis, Infect. Immun., 48, 409–416.PubMedGoogle Scholar
  2. 2.
    Ahmed I. and Patton T.P., 1986, Selective intraocular delivery of liposome encapsulated inulin via the non-corneal absorption route, Inter. J. Pharm., 14, 163–167.CrossRefGoogle Scholar
  3. 3.
    Al Khouri Fallouh N., Roblot-Treupel L., Fessi H., Devissaguet J.P. and Puisieux F., 1986, Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules, Int. J. Pharm., 28: 125–132.CrossRefGoogle Scholar
  4. 4.
    Allen T.M., 1988, Interaction of liposomes and other drug carriers with the mononuclear phagocyte system, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 37–50.Google Scholar
  5. 5.
    Allen T. and Chonn A., 1987, Large unilamellar liposomes with low uptake into the reticuloendothelial system, FEBS Lett., 223: 42–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Alving C.R., Steck E.A., Chapman W.L., Waits V.B., Hendricks L.D., Swartz G.M. and Handson W.L., 1978, Therapy of leishmaniasis, superior efficacies of liposome-encapsulated drugs, Proc. Natl. Acad. Sci., USA, 75: 2959–2963.PubMedCrossRefGoogle Scholar
  7. 7.
    Barker-Woudenberg I.A.J.M., Lokerse A.F., Vink Van Den Berg J.C. and Roerdink F.H., 1988, Liposome-encapsulated ampicillin against Listeria monocytogenes in vivo and in vitro, Infection. 16, Suppl. 2: S165–S174.CrossRefGoogle Scholar
  8. 8.
    Barbet J., Machy P. and Leserman L.D., 1985, Pilotage des liposomes, in “Les liposomes, Applications Thérapeutiques”, F. Puisieux et J. Delattre, Eds., Lavoisier Tec. et Doc, Paris, 189–204.Google Scholar
  9. 9.
    Barratt G., Tenu J.P., Yapo A. and Petit J.P., 1986, Preparation and characterization of liposomes containing mannosylated phospholipids capable of targeting drugs to macrophages, Biochim. Biophvs. Acta. 862: 153–164.CrossRefGoogle Scholar
  10. 10.
    Bassett J.B., Tacker J.R., Anderson R.U. and Bostwick D., 1988, Treatment of experimental bladder cancer with hyperthermia and phase transition liposomes containing methotrexate, J. Urol., 139: 634–636.PubMedGoogle Scholar
  11. 11.
    Benita S. et Devissaguet J.P., 1985, Pharmacocinétique des liposomes et des principes actifs encapsulés dans les liposomes, m “Les Liposomes, Applications Thérapeutiques”, F. Puisieux and J. Delattre, Eds., Lavoisier, Tec. et Doc, Paris, 173–188.Google Scholar
  12. 12.
    Benoit J.P., 1985, Microencapsulation et chimio-embolisation, in “Formes Pharmaceutiques Nouvelles. Aspects Technologique, Biopharmaceutique et Médical”, P. Buri, F. Puisieux, E. Doelker and J.P. Benoit, Eds., Lavoisier, Tec. et Doc, Paris 613–656.Google Scholar
  13. 13.
    Benoit J.P. and F. Puisieux, 1986, Microcapsules and microspheres for embolization and chemoembolization, in “Polymeric Nanoparticles and Microspheres”, P. Guiot and P. Couvreur, Eds., CRC Press, Boca Raton, 137–174.Google Scholar
  14. 14.
    Bienvenue A. and Philippot J., 1985, Interaction des liposomes avec les cellules, in “Les Liposomes, Applications Thérapeutiques”, F. Puisieux and J. Delattre, Eds., Lavoisier, Tec. et Doc, Paris, 147–171.Google Scholar
  15. 15.
    Black C.D.V., Watson G.J. and Ward R.J., 1977, The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis, Trans. R. Soc. Trop. Med. Hyg., 71: 550–554.PubMedCrossRefGoogle Scholar
  16. 16.
    Blank M.L., Byrd B.L., Cress T.A., Wasburn L.C. and Synder F., 1984, Liposomal preparations of calcium or zinc-DTPA have a high efficacy for removing colloidal ytterbium-169 from rat tissues, Toxicology. 30: 275–282.PubMedCrossRefGoogle Scholar
  17. 17.
    Bonte F., Taupin C. and Puisieux F., 1986, Liposomes de surfactant artificiel et transition de phase, Rev. Mal. Resp., 3: 129–132.Google Scholar
  18. 18.
    Collins D., Norley S., Rouse B. and Huang L., 1988, Liposomes as carriers for antitumor and antiviral drugs: pH sensitive immunoliposomes and sustained release immunoliposomes, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 761–770.Google Scholar
  19. 19.
    Connor J., Sullivan S. and Huang L., 1985, Monoclonal antibodies and liposomes, Pharmac. Ther., 28: 341–365.CrossRefGoogle Scholar
  20. 20.
    Connor J., Yatvin M.B. and Huang L., 1984, pH-sensitive liposomes: acid induced liposome fusion, Proc. Natl. Acad. Sci., USA, 81:1715–1718.PubMedCrossRefGoogle Scholar
  21. 21.
    Coune A., 1988, Liposomes as drug delivery systems in the treatment of infectious diseases. Potential applications and clinical experience, Infection. 16: 141–147.PubMedCrossRefGoogle Scholar
  22. 22.
    Damge C., Michel C., Aprahamian M. and Couvreur P., 1988, New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier, Diabetes. 37: 246–251.PubMedCrossRefGoogle Scholar
  23. 23.
    Dapergolas G., Neerunjun E.D. and Gregoriadis G., 1976, Penetration of target areas in the rat by liposome-associated bleomycin, glucose-oxidase and insulin, FEBS Lett., 63: 235–240.PubMedCrossRefGoogle Scholar
  24. 24.
    Das N., Basu M.K. and Das M.K., 1988, Oral application of insulin encapsulated liposomes, Biochem. Inter., 16: 983–989.Google Scholar
  25. 25.
    Delattre J., Laham A., Claperon N., Chapat S., Couvreur P., Puisieux F. and Rossignol P., 1989, Nouvelles perspectives offertes par l’administration de liposomes d’adénosine-triphosphate (ATP) dans l’ischémie cérébrale expérimentale, STP Pharma., 5, 92–98.Google Scholar
  26. 26.
    Delattre J. et Vasson M.P., 1985, Stabilité des liposomes dans les liquides biologiques. Effets de certains constituants, in “Les Liposomes, Applications Thérapeutiques”, F. Puisieux and J. Delattre, Eds., Lavoisier, Tec. et Doc, Paris 115–145.Google Scholar
  27. 27.
    Eichler H.G., Senior J., Stadler A., Gasic S., Pfundner P. and Gregoriadis G., 1988, Kinetics and disposition of fluoresceinlabelled liposomes in healthy human subjects, Eur. J. Clin. Pharmacol., 34:475–479.PubMedCrossRefGoogle Scholar
  28. 28.
    Eppstein D.A., Van Der Pas M.A., Fraser-Smith E.B., Kurahara C.G., Felgner P.L., Matthews T.R., Waters R.V., Venuti M.C., Jones G.H., Mehta R. and Lopez-Berestein G., 1986, Liposome-encapsulated muramyldipeptide analogue enhances non-specific host immunity, Int. J. Immunother., II, (2): 115–126.Google Scholar
  29. 29.
    Fidler I.J., 1986, Optimization and limitations of systemic treatment of murine melanoma métastases with liposomes containing muramyl tripeptide phosphatidylethanolamine, Cancer Immunol. Immunother., 21:169–173.PubMedCrossRefGoogle Scholar
  30. 30.
    Fidler I.J., Raz A., Fogler W.E., Kirsh R., Bugelski P. and Poste G., 1980, Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages, Cancer Res., 40: 4460–4464.PubMedGoogle Scholar
  31. 31.
    Fidler I.J., Sone S., Fogler W.E. and Barnes Z.L., 1981, Eradication of spontaneous métastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyldipeptide, Proc. Natl. Acad. Sci., USA, 78: 1680–1681.PubMedCrossRefGoogle Scholar
  32. 32.
    Fruhling J., Coune A., Ghanem G., Sculier J.P., Verbis A., Brassine C., Laduron C. and Hildebrand J., 1984, Distribution in man of 111In-labelled liposomes containing a water-insolubles antimitotic agent, Nucl. Med. Commun. 5: 205–208.PubMedGoogle Scholar
  33. 33.
    Gabizon A.A. and Barenholz Y., 1988, Adriamycin containing liposomes in cancer chemotherapy, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 365–379.Google Scholar
  34. 34.
    Gregoriadis G., 1973, Drug entrapment in liposomes, FEBS Lett., 36: 292–296.PubMedCrossRefGoogle Scholar
  35. 35.
    Gregoriadis G., 1978, Liposomes in the therapy of lysosomal storage diseases, Nature. 275: 695–696.PubMedCrossRefGoogle Scholar
  36. 36.
    Gregoriadis G., 1988, Liposomes as Drug Carriers. Recent Trends and Progress, J. Willey and Sons, Chichester, New York, Brisbane, Toronto, Singapore.Google Scholar
  37. 37.
    Gregoriadis G., 1988, Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 3–18.Google Scholar
  38. 38.
    Gregoriadis G., Leathwood P.D. and Ryman B.E., 1971, Enzyme entrapment in liposomes, FEBS Lett., 14: 95–99.PubMedCrossRefGoogle Scholar
  39. 39.
    Hemker H.C., Muller A.D., Hermens W.T. and Zwaal R.F.A., 1980, Oral treatment of haemophilia A by gastrointestinal absorption of factor VIII entrapped in liposomes, Lancet. 12: 70–71.CrossRefGoogle Scholar
  40. 40.
    Herman E.H., Rahman A., Ferrans V.J., Vick J.A. and Schein P.S., 1983, Prevention of chronic doxorubicin cardio-toxicity in beagles by liposomial encapsulation, Cancer Res., 43: 5427–5432.PubMedGoogle Scholar
  41. 41.
    Hirano K. and Hunt A., 1985, Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration, J. Pharm. Sci., 74, 915–921.PubMedCrossRefGoogle Scholar
  42. 42.
    Hwang K.J. and Beaumier P.L., 1988, Disposition of liposomes in vivo, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 19–35.Google Scholar
  43. 43.
    Jaskierowicz D., Genissel F., Roman V., Berleur F. and Fatome M., 1985, Oral administration of liposome-entrapped cysteamine and the distribution pattern in blood, liver and spleen, Int. J. Radiat. Biol., 47: (6), 615–619.CrossRefGoogle Scholar
  44. 44.
    Juliano R.L., 1981, Liposomes as a drug delivery system, Trends Pharmacol., Sci. Feb., 39-41.Google Scholar
  45. 45.
    Juliano R.L. and Lopez-Berestein G., 1985, New lives for old drugs: liposomal drug delivery systems reduce the toxicity but not the potency of certain chemotherapeutic agents, Pharm. Inter., July: 164-167.Google Scholar
  46. 46.
    Khato J., Del Campo A.A. and Sieber S.M., 1983, Carrier activity of sonicated small liposomes containing melphalan to regional lymph nodes of rats, Pharmacol., 26: 230–240.CrossRefGoogle Scholar
  47. 47.
    Kim S., Kim D.J. and Howell S.B., 1987, Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes, Cancer Chemother. Pharmacol., 19, 307–310.PubMedCrossRefGoogle Scholar
  48. 48.
    Kimura T., 1988, Transmucosal passage of liposomal drugs, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 635–647.Google Scholar
  49. 49.
    Kiwada H., Sato J., Yamada S. and Kato Y., 1986, Feasibility of magnetic liposomes as a targeting device for drugs, Chem. Pharm. Bull., 34:4253–4258.PubMedCrossRefGoogle Scholar
  50. 50.
    Knepp V.M., Hinz R.S., Szoka F.C. and Guy R.H., 1988, Controlled drug release from a novel liposomal delivery system. I. Investigation of transdermal potential, J. Control. Release, 5: 211–221.CrossRefGoogle Scholar
  51. 51.
    Koff W.C. and Fidler I.J., 1984, Human monocytes activated by immunomodulators in liposomes lyses Herpes-virus-infected but not normal cells, Science. 224: 1007–1009.PubMedCrossRefGoogle Scholar
  52. 52.
    Laham A., Claperon N., Durussel J.J., Fattal E., Delattre J., Puisieux F. Couvreur P. and Rossignol P., 1987, Liposomally entrapped ATP: improved efficiency against experimental brain ischemia in the rat, Life Sci., 40: 2011–2016.PubMedCrossRefGoogle Scholar
  53. 53.
    Laham A., Claperon N., Durussel J.J., Fattal E., Delattre J., Puisieux F., Couvreur P. and Rossignol P., 1988, Intracarotidal administration of liposomally-entrapped ATP: improved efficiency against experimental brain ischemia, Pharmacol. Research Comm., 20: 699–705.CrossRefGoogle Scholar
  54. 54.
    Leserman L.D., Barbet J., Kourilsky F. and Weinstein J., 1980, Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A, Nature. 288: 602–604.PubMedCrossRefGoogle Scholar
  55. 55.
    Lopez-Berestein G., 1988, Liposomal amphotericin B in antimicrobial therapy, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., [pmJ. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 345–352.Google Scholar
  56. 56.
    Lopez-Berestein G., Fainstain V., Hopfer R., Mehta K., Sullivan M.P., Keating M., Rosenblum M.G., Mehta R., Luna M., Hersh E.M., Reuben J., Juliano R.L. and Bodey G.P., 1985, Liposomal Amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study, J. Infect. Dis., 151:704–710.PubMedCrossRefGoogle Scholar
  57. 57.
    Lopez-Berestein G., Hoffer R.L., Mehta R., Mehta K., Hersh E.M. and Juliano R.L., 1984, Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated Amphotericin B, Antimicrob. Agents. Chemother., 25: 366–367.PubMedCrossRefGoogle Scholar
  58. 58.
    Lopez-Berestein G., Mehta K., Mehta R., Juliano R.L. and Hersh E.M., 1983, The activation of human monocytes by liposome-encapsulated muramyldipeptide analogues, J. Immunol., 130: 1500–1502.PubMedGoogle Scholar
  59. 59.
    Machy P. and Leserman L., 1987, Les liposomes en Biologie Cellulaire et Pharmacologie. Les Editions Inserm, J. Libbey Eurotext Ltd., Paris.Google Scholar
  60. 60.
    Margolis L.B., 1988, Cell interactions with solid and fluid liposomes in vitro: lessons for “liposomologists” and cell biologists, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 75–92.Google Scholar
  61. 61.
    Mezei M., 1988, Liposomes in the topical application od drugs: a review, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 663–677.Google Scholar
  62. 62.
    Mihalko P.J., Schreier H. and Abra R.M., 1988, Liposomes: a pulmonary perspective, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 679–694.Google Scholar
  63. 63.
    Morimoto K., Nakamura T., Nakai T. and Morisaka K., 1988, Effects of liposomes on permeability of various compounds through rabbit corneas, Arch. Int. Pharmacodyn., 293: 7–13.PubMedGoogle Scholar
  64. 64.
    Nagata M., Yotsuyanagi T. and Ikeda K., 1988, A two-step model of disintegration kinetics of liposomes in bile salts, Chem. Pharm. Bull., 36: 1508–1513.PubMedCrossRefGoogle Scholar
  65. 65.
    Nayar R., Fidler I.J. and Schroit A.J., 1988, Potential applications of pH-sensitive liposomes as drug delivery systems, In “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 771–782.Google Scholar
  66. 66.
    Nayar R. and Schroit A.J., 1985, Generation of pH-sensitive liposomes. Use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine, Biochemistry, 24: 5967–5971.PubMedCrossRefGoogle Scholar
  67. 67.
    New R.R.C., Chance M.L., Thomas S.C. and Peters W., 1978, Antileishmanial activity of antimonials entrapped in liposomes, Nature. 272:556–561.CrossRefGoogle Scholar
  68. 68.
    Onuma M., Odawara T., Watarai S., Aida Y. Ochiai K., Syuto B., Matsumoto K., Yasuda T., Fujimoto Y., Izawa H. and Kawakami Y., 1986, Antitumor effect of adriamycin entrapped in liposomes conjugated with monoclonal antibody against tumor-associated antigen of bovine leukemia cells, Cancer Res. (Gann), 77, 1161–1167.Google Scholar
  69. 69.
    Ostro M.J., 1987, Liposomes from Biophysics to Therapeutics, M. Dekker Inc., New York, Basel.Google Scholar
  70. 70.
    Patel H.M., 1985, Liposomes as a controlled-release system, Biochem. Soc. Trans., 13: 513–516.PubMedGoogle Scholar
  71. 71.
    Patel K.R., Li M.P. and Baldeschwieler J.D., 1983, Suppression of liver uptake of liposomes by dextran sulfate 500, Proc. Natl. Acad. Sci., USA, 80:6518–6522.PubMedCrossRefGoogle Scholar
  72. 72.
    Payne N.I., Cosgrove R.F., Green A.P. and Liu L., 1987, In vivo studies of Amphotericin B liposomes derived from protoliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice, J. Pharm. Pharmacol., 39: 24–28.PubMedCrossRefGoogle Scholar
  73. 73.
    Perez-Soler R., Khokhar A.R. and Lopez-Berestein G., 1988, Development of lipophilic cisplatin analogs encapsulated in liposomes, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 401–417.Google Scholar
  74. 74.
    Phillips N.C., Moras M.L., Chedid L., Lefrancier P. and Bernard J.M., 1985, Activation of alveolar macrophage tumoricidal activity and eradication of experimental métastases by freeze-dried liposomes containing a new lipophilic muramyldipeptide derivative, Cancer Res., 45: 128–134.PubMedGoogle Scholar
  75. 75.
    Phillips N.C., Moras M.L., Chedid L., Petit J.F., Tenu J.P., Lederer E., Bernard J.M. and Lefrancier P., 1985, Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-Alanyl-Cholesterol (MTP-CHOL), J. Biol. Response Mod., 4: 464–474.PubMedGoogle Scholar
  76. 76.
    Poste G., 1983, Liposome Targeting in vivo: problems and opportunities, Biol. Cell., 47: 19–38.Google Scholar
  77. 77.
    Poste G., Kirsh R., Fogler W. and Fidler I.J., 1979, Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes, Cancer Res., 39: 881–892.PubMedGoogle Scholar
  78. 78.
    Puisieux F., 1985, Les liposomes et leur emploi en thérapeutique. Bilan des recherches réalisées, in “Les Liposomes. Applications Thérapeutiques”, F. Puisieux and J. Delattre, Eds., Lavoisier, Tec. et Doc, Paris, 205–253.Google Scholar
  79. 79.
    Puisieux F. and Delattre J., 1985, Les Liposomes. Applications Thérapeutiques, Lavoisier, Tec. et Doc, Paris.Google Scholar
  80. 80.
    Puisieux F. et Roblot-Treupel L., 1989, Vectorisation et vecteurs de médicaments, 1989, STP Pharma. 1989, 5, 107–113.Google Scholar
  81. 81.
    Rahman A., Ganjei A. and Neefe J.R., 1986, Comparative immunotoxicity of free doxorubicin and doxorobucin encapsulated in cardiolipin lipsomes, Cancer Chemother. Pharmacol., 16: 28–34.PubMedGoogle Scholar
  82. 82.
    Rahman A. and Schein P.S., 1988, Use of liposomes in cancer chemotherapy, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed. J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 381–400.Google Scholar
  83. 83.
    Rahman Y.E. and Wright B.J., 1975, Liposomes containing chelating agents. Cellular penetration and a possible mechanism of metal removal, J. Cell. Biol., 65: 112–117.PubMedCrossRefGoogle Scholar
  84. 84.
    Reszka R., Fichtner L., Nissen E., Arnot D. and Ladhoff A.M., 1987, Preparation, characterization, therapeutic efficacy and toxicity of liposomes containing the antitumour drug cisdichlorodiamine-platinum (II), J. Microencaps., 4: 201–212.CrossRefGoogle Scholar
  85. 85.
    Saiki I., Sone S., Fogler W.E., Kleinerman E.S., Lopez-Berestein G. and Fidler I.J., 1985, Synergism between human recombinant λ-interferon and muramyldipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes, Cancer Res., 46: 6188–6193.Google Scholar
  86. 86.
    Scherphof G., Van Leeuven B., Wilschut J. and Damen J., 1983, Exchange of phosphatidylcholine between small unilamellar liposomes and human plasma high-density lipoprotein involves exclusively the phospholipid in the outer monolayer of the liposomal membrane, Biochim. Biophys. Acta. 732: 595–599.PubMedCrossRefGoogle Scholar
  87. 87.
    Sculier J.P., Coune A., Meunier F., Brassinne C., Laduron C., Hollaert C., Collette N., Heymans C. and Klastersky J., 1988, Pilot study of Amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections, Eur. J. Cancer Clin. Oncol., 24: 527–528.PubMedCrossRefGoogle Scholar
  88. 88.
    Sells R.A., Gilmore L.T., Owen R.R., New R.R.C. and Stringer R.E., 1987, Reduction in doxorubicin toxicity following liposomal delivery, Cancer Treat. Rev., 14: 383–387.PubMedCrossRefGoogle Scholar
  89. 89.
    Senior J., 1987, Fate and behaviour of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. Therapeutic Drug Carrier Systems. 3: 123–125.Google Scholar
  90. 90.
    Senior J., Crawley J.C.W. and Gregoriadis G., 1985, Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection, Biochim. Biophys. Acta. 839: 1–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Senior J. and Gregoriadis G., 1984, Role of lipoproteins in stability and clearance of liposomes administered to mice, Biochem. Soc. Trans., 12:339–340.PubMedGoogle Scholar
  92. 92.
    Sone S., Tandon P., Utsugi T., Ogawara M., Shimizu E., Nh A. and Ogura T., 1986, Synergism of recombinant human interferon gamma with liposome-encapsulated muramyltripeptide in activation of the tumoricidal properties of human monocytes, Int. J. Cancer. 38: 495–500.PubMedCrossRefGoogle Scholar
  93. 93.
    Spanjer H.H., Van Galen M., Roerdink F.H., Regts J. and Scherphof G.L., 1986, Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition, Biochim. Biophvs. Acta. 863: 224–230.CrossRefGoogle Scholar
  94. 91.
    Steerenberg P.A., Storm G., De Groot G., Claessen A., Bergers J.J., Franken M.A.M., Van Hoesel Q.G.C.M., Wubs K.L. and DE Jong W.H., 1988, Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution, Cancer Chemother. Pharmacol., 21: 299–307.PubMedCrossRefGoogle Scholar
  95. 95.
    Stevensen R.W., Patel H.M., Parsons J.A. and Ryman B., 1982, Prolonged hypoglycemic effect in diabetic dogs due to subcutaneous administration of insulin in liposomes, Diabetes. 31: 506–511.CrossRefGoogle Scholar
  96. 96.
    Storm G., 1987, Liposomes as delivery system for doxorubicin in cancer chemotherapy. Thesis Rijksuniversity of UTRECHT.Google Scholar
  97. 97.
    Svenson C.E., Popescu M.C. and Ginsberg R.S., 1988, Preparation and use of liposomes in the treatment of microbial infections, Crit. Rev. Microbiol., 15: S1–S31.CrossRefGoogle Scholar
  98. 98.
    Takada M., Yuzuriha K., Katayama K., Iwamoto K. and Sunamoto J., 1984, Increased lung uptake of liposomes coated with polysaccharides, Biochim. Biophvs. Acta, 802: 237–244.CrossRefGoogle Scholar
  99. 99.
    Taniguchi K., Itakura K., Yamazawa N., Morisaki K., Hayashi S. and Yamada Y., 1988, Efficacy of a liposome preparation of antiinflammatory steroid as an ocular drug-delivery system, J. Pharmacol. Dvn., 11: 39–46.Google Scholar
  100. 100.
    Trembley C., Barza M., Fiore C. and Szoka F., 1984, Efficacy of liposome-intercalated Amphotericin B in the treatment of systemic candidiasis in mice, Antimicrob. Agents and Chemother., 26: 170–173.CrossRefGoogle Scholar
  101. 101.
    Van Hoesel Q.G.C.M., Steerenberg P.A., Crommelin D.J.A., Van Dijk A., Van Oort W., Klein S., Douze J.M.C., DE Wildt D.J. and Hillen F.C., Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the Lou/M WS1 rat, Cancer Res., 44: 3698-3705.Google Scholar
  102. 102.
    Vidal M., Bienvenue A. Sainte-Marie J. and Philippot J., 1984, The influence of the internal content of negatively charged liposomes on their interaction with high-density lipoprotein, Eur. J. Biochem., 138: 399–405.PubMedCrossRefGoogle Scholar
  103. 103.
    Walde P., Sunamoto J. and O’Connor C.J., 1987, The mechanism of liposomal damage by taurocholate, Biochim. Biophvs. Acta. 905: 30–38.CrossRefGoogle Scholar
  104. 104.
    Waser P.G., Muller U., Kreuter J., Berger S., Munz K., Kaiser E. and Pfluger B., 1987, Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice, Inter. J. Pharm., 39: 213–227.CrossRefGoogle Scholar
  105. 105.
    Weiner N. and Chiang C.M., 1988, Gastrointestinal uptake of liposomes, in “Liposomes as Drug Carriers. Recent Trends and Progress”, G. Gregoriadis, Ed., J. Wiley and Sons, Chichester, New York, Brisbane, Toronto, Singapore, 599–607.Google Scholar
  106. 106.
    Weingarten C., Moufti A., Desjeux J.F., Luong T.T., Durand G., Devissaguet J.P. and Puisieux F., 1981, Oral ingestion of insulin liposomes: effects of the administration route, Life Sci., 28: 2747–2752.PubMedCrossRefGoogle Scholar
  107. 107.
    Weinstein J.N., 1984, Liposomes as drug carriers in cancer therapy, Cancer Treat. Rep., 68: 127–135.PubMedGoogle Scholar
  108. 108.
    Weinstein J.N., 1987, Liposomes in the diagnosis and treatment of cancer, in “Liposomes from Biophysics to Therapeutics”, M.J. Ostro, Ed., M. Dekker, Inc., New York, Basel, 277–338.Google Scholar
  109. 109.
    Wohlrab W. and Lasch J., 1987, Penetration kinetics of liposomal hydrocortisone in human skin, Dermatologica. 174: 18–22.PubMedCrossRefGoogle Scholar
  110. 110.
    Yatvin M.B., Kreutz W., Horwitz B.A. and Shinitzky M., 1980, pH-sensitive liposomes: possible clinical implications, Science. 210: 1253–1255.PubMedCrossRefGoogle Scholar
  111. 111.
    Yatvin M.B., Muhlensiepen H., Porschen W., Weinstein J.N. and Feinendeken L.E., 1981, Selective delivery of liposome-associated cis-dichlorodiammineplatinum (II) by heat and its influence on tumor drug uptake and growth, Cancer Res., 41: 1602–1607.PubMedGoogle Scholar
  112. 112.
    Yatvin M.B., Weinstein J.N., Dennis W.H. and Blumenthal R., 1978, Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202: 1290–1293.PubMedCrossRefGoogle Scholar
  113. 113.
    Yemul S.S., Berger C., Estabrook A., Suarez S., Edelson R. and Bayley H., 1987, Selective killing of T lymphocytes by phototoxic liposomes, Proc. Natl. Acad. Sci., USA, 84: 246–250.PubMedCrossRefGoogle Scholar
  114. 114.
    Zaguri D., 1980, Les cellules tueuses, La Recherche. 114: 928–937.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • F. Puisieux
    • 1
  • G. Barratt
    • 1
  • L. Roblot-Treupel
    • 1
  • J. Delattre
    • 1
    • 2
  • P. Couvreur
    • 1
  • J. Ph. Devissaguet
    • 1
  1. 1.Laboratoire de Pharmacie Galénique et de Biopharmacie, URA CNRS 1218Université de Paris XIChâteany-Malabry CédexFrance
  2. 2.Laboratoire de BiochimieUniversité de Paris VParisFrance

Personalised recommendations